Status:
WITHDRAWN
Clinical Outcomes of IVUS-guided Stenting Using the Boston Scientific Vici® Venous Stent System in Treating Patients With Chronic Non-malignant Iliofemoral Vein Obstruction
Lead Sponsor:
Boston Scientific Corporation
Conditions:
Chronic Venous Disorder
Venous Outflow Obstruction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The APAC VICI Study is a prospective, non-randomized, multicenter, single-arm study. The purpose of this study is to evaluate the clinical results of using the Boston Scientifc's Vici Venous Stent (Vi...
Eligibility Criteria
Inclusion
- Key
- Ethnic Chinese subjects of age ≥ 18 years (or meet age requirements per local law)
- Subjects willing to provide written informed consent prior to the study and AND willing to comply with all follow-up evaluations at the specified times
- Subjects with presence of unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a \> 50% reduction in target vessel lumen diameter measured by venogram and/or IVUS during procedure
- Clinically significant venous obstruction defined as meeting at least one of the following clinical indicators:
- Clinical severity class of CEAP classification ≥ 3
- rVCSS Pain Score ≥ 2
- Negative pregnancy test in female subjects of potential child-bearing
- Intention to stent the target lesion only with the Vici Stent(s)
- Key
Exclusion
- Pre-Procedural EC--
- Subjects with presence or history of clinically significant pulmonary emboli within 6 months prior to enrollment.
- Subjects with venous obstruction that extends into the inferior vena cava
- Subjects with contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof with planned treatment within 30 days after enrollment
- Subjects with a life expectancy \< 12 months
- Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study (Note: subjects who plan to become pregnant after 12-month follow-up visit may be included in the trial at the discretion of treating physician)
- A. Subjects with uncontrolled or active coagulopathy OR
- B. Subjects with known uncorrectable bleeding diathesis with the following definitions:
- Uncorrected INR ≥ 2.0 or aPTT ≥ 1.5X normal local lab value
- Platelet count \< 80,000
- Subjects with uncorrected hemoglobin of ≤ 9 g/dL
- Subjects with an estimated glomerular filtration rate (eGFR) \< 30 mL/min. In patients with diabetes mellitus, eGFR \< 45 mL/min.
- Subjects have known hypersensitivity to nickel or titanium
- Subjects have contrast agent allergy that cannot be managed adequately with pre-medication
- Subjects will have intended concurrent thrombolysis or thrombectomy procedure OR intended or planned (within 30 days) adjuvant procedure such as creation of temporary AV fistula, placement of IVC filter, endovenectomy or saphenous vein ablation
- Subjects currently participating in another drug or device clinical trial (participation in observational studies is acceptable)
- Subjects judged to be a poor candidate by the primary investigator
- Subjects who have had any prior surgical or endovascular intervention of the target vessel
- Intra-Procedural:
- Subjects in whom the lesions cannot be traversed with a guide wire
- Subjects where the obstruction extends into the inferior vena cava or below the level of the lesser trochanter
- Subjects whose vein diameters are not within limits stated in the Instructions for Use of study device as determined by venogram and/or IVUS
- Subjects who do not meet the venogram or IVUS binary stenosis by the definition above (IC3), as determined by the treating physician
- Subjects who are judged by treating physician to have a lesion that prevents completed inflation of a balloon dilation catheter or proper placement of the stent or the stent delivery system
Key Trial Info
Start Date :
December 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04856592
Start Date
December 31 2021
End Date
December 31 2023
Last Update
November 1 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.